Status:
COMPLETED
EMD 521873 Plus Radiotherapy in Non Small Cell Lung Cancer (NSCLC)
Lead Sponsor:
Merck KGaA, Darmstadt, Germany
Conditions:
Lung Cancer
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Primary trial objective in this single arm trial is to assess the safety and tolerability of Selectikine (EMD 521873) given in combination with and local tumor irradiation and to determine whether the...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed NSCLC stage IIIb with malignant pleural effusion or stage IV
- Pulmonary primary tumor or at least one NSCLC metastasis in the lung measuring at least 1 cm in diameter and eligible for local radiation with 20 Gy
- Disease control (partial remission or stable disease) after 4 cycles of platinum-based first-line chemotherapy whereby the time between the last dose of first-line chemotherapy and start of trial treatment should not be longer than 8 weeks
- Male or female, aged ≥18 years of age
- Signed written informed consent
- Effective contraception for male and female subjects of childbearing age
- ECOG performance status 0 or 1
- Adequate hematological function defined by WBC ≥3 x 10\^9/L, neutrophils ≥1.5 x 10\^9/L, lymphocyte count ≥0.5 x 10\^9/L, platelet count ≥100 x 10\^9/L; hemoglobin ≥9 g/dL
- Estimated creatinine clearance ≥50 mL/min according to the Cockcroft - Gault formula or 24-h urine sampling
- Adequate hepatic function defined by a total bilirubin level ≤1.5 times the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤5 x ULN
Exclusion
- Requirement for immunosuppressive treatment with the exception of inhalative corticosteroids or low-dose systemic corticosteroids (prednisone equivalent dose ≤10 mg/day)
- Systemic autoimmune disease (e.g. lupus erythematodes, rheumatoid arthritis)
- Organ transplant recipients
- Active infections (including HIV, hepatitis B and C, tuberculosis)
- Known or clinically suspected brain metastases
- Active cardiovascular/cerebrovascular disease (e.g. symptomatic coronary vascular disease, congestive heart failure ≥ NYHA II, LVEF \<50%, ventricular arrhythmia requiring medication, myocardial infarction or stroke) within previous 6 months
- Pericardial effusion
- Major impairment in pulmonary function: forced expir¬atory volume in 1 second (FEV1) \<50% and diffusion capacity for carbon monoxide (DLCO) \<50% of normal limit
- Any other significant disease that in the Investigator's opinion would exclude the subject from the trial
- Known conditions associated with necroses of non-tumor bearing tissues (e.g. esophageal or gastroduodenal ulcers, ischemic bowel disease, chronic inflammations)
- Pregnancy or lactation
- Radiotherapy, chemotherapy, major surgery, biological therapy or any investigational drug within 30 days prior to the start of trial treatment
- Requirement for concurrent systemic anticancer treatment (chemotherapy, biological therapy)
- Pretreatment with anti-EGFR antibodies or tyrosine kinase inhibitors
- Participation in another interventional clinical trial within the past 30 days before start of trial treatment
- Known alcohol or drug abuse
- Any psychiatric condition that would prohibit the understanding or rendering of the informed consent
- Legal incapacity or limited legal capacity
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00879866
Start Date
April 1 2009
End Date
September 1 2012
Last Update
June 23 2014
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Thoracic Oncology, Netherlands Cancer Instiute - Antoni van Leeuwenhoek Hospital
Amsterdam, Netherlands
2
Department of Pulmonology, Academic Hosptial Maastricht
Masstricht, Netherlands
3
Department of Medical Oncology (452), Radboud UMC Nijmegen
Nijmegen, Netherlands